MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward

MannKind Corporation (MNKD) announced an update on their ongoing clinical study.

The study “A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Clinical Study of the Safety, Tolerability, and Pharmacokinetics of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis” tests an inhaled form of nintedanib in idiopathic pulmonary fibrosis. It aims to show if this new dry powder inhaler is safe and well tolerated, which could open a new path in treating this serious lung disease.

MNKD-201 is a dry powder version of nintedanib designed for inhalation, rather than as an oral pill. The goal is to deliver the drug straight to the lungs, which may allow similar or better effect with lower total exposure and possibly fewer side effects.

The trial is an interventional Phase 1b study in patients with idiopathic pulmonary fibrosis. Patients are randomly assigned to receive either MNKD-201 or placebo, and neither they nor their doctors know who gets which treatment during the study.

The design uses a sequential model with multiple ascending doses, so lower doses are tested first before moving to higher doses. The main aim is treatment focused, looking at safety and how the drug moves through the body, not yet at long term disease outcomes.

In Cohort 1, patients receive a target dose of MNKD-201 or placebo by inhaler three times a day for seven days. In Cohort 2, patients receive a higher dose of MNKD-201 or placebo twice a day for seven days, which helps map out a dose range for future larger trials.

The study was first submitted on January 7, 2026, marking the formal launch of this early clinical program. The most recent update was filed on April 13, 2026, signaling that the protocol and status information have been refreshed and that recruitment remains active.

Primary completion and final completion dates have not yet been posted, which is typical for an early phase study still in the recruiting stage. Investors should assume that key readouts on safety and drug levels will likely come before any larger, longer efficacy trials begin.

For MannKind Corporation, this update matters because it extends the firm’s pipeline beyond its core diabetes franchise. A successful inhaled nintedanib program could support a higher valuation multiple by showing that its dry powder platform works in fibrotic lung disease as well.

Investor sentiment may improve on signs of steady trial progress, especially if early safety data later look clean compared with oral nintedanib, which can be hard to tolerate. Competitors like Boehringer Ingelheim with oral nintedanib and other fibrosis players set a high bar, but an inhaled option could carve out a niche if it shows a better balance of benefit and side effects.

The study is currently recruiting and remains active, with the latest information and future updates available on the ClinicalTrials.gov portal under its listed identifier.

To learn more about MNKD’s potential, visit the MannKind Corporation drug pipeline page.